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Historically, female athletes only compete against other female athletes, 
males against males. Over the last few decades, this concept and definition of 
female and male in athletics has been a hotly-discussed topic. This is especially so 
at the highest level of international track and field, where the quest to eliminate 
cheaters who consume illicit performance enhancing drugs is a top priority. As 
technology has improved, there is a greater ability to determine what substances 
give an unfair competitive advantage and detect when those banned substances are 
present in an athlete. The understanding of human biology has also developed 
exceedingly. While this growth in understanding has been immensely beneficial to 
general human existence, these same development seem to be taking a toll on 
female athletes who are intersex or hyperandrogenic. 
II. Historical & legal overview of the problem 
Intersex is a broad term “used for a variety of conditions in which a person 
is born with a reproductive or sexual anatomy that doesn’t seem to fit the typical 
definitions of female or  
male.”1 There are various ways intersex can present itself. For example, “a person 
might be born appearing to be female on the outside, but having mostly male-
typical anatomy on the inside.”2 In another instance, a “person may be born with 
mosaic genetics, so that some of her cells have XX chromosomes and some of them 
have XY.”3 Intersex characteristics are not always present at birth. Many times 
people do not discover they are intersex until puberty or upon discovering 
infertility.4 Often people never discover it during life but it is discovered during an 
autopsy.5  
Hyperandrogenism is a medical condition causing a person to produce high 
levels of hormones.6 While there are various forms of hyperandrogenism, the 
International Association of Athletics Federations (IAAF) regulates the form of 
hyperandrogenism in intersex female athletes where they produce testosterone at 
much higher levels than the female average.7 The IAAF has taken the position that 
hyperandrogenic female athletes should not be allowed to compete until they take 
action to suppress naturally occurring high levels of testosterone.8  
                                               





6 Hyperandrogenism explained and what it means for athletics, USA Today, Aug. 2, 2016. 
7 Id. 
8 Sean Ingle, Sebastian Coe: IAAF right to seek court ruling over hyperandrogenism issue, The Guardian, Aug. 12, 
2017.  




Testing for the sex of an athlete, has been around in track and field for 
decades.  In fact, the use of anabolic doping agents was first recorded at the 1952 
Olympic Games, with wide belief that the first use was German athletes at the 1936 
Olympic Games.9 First, it was a basic physical examination; later it was a 
chromosome test. In the 1980s, however, the IAAF considered testosterone levels 
when determining who was “woman enough” to participate in competitions after 
Spanish hurdler Maria Martinez-Patino was unfairly thrown off Spain’s Olympic 
team based on a chromosome test.10 In 2011, the IAAF began “a three-stage 
medical examination process if it suspected a female athlete had 
hyperandrogenism.”11 Between the 1980s and 2011, the IAAF handled the issue of 
intersex female athletes and hyperandrogenism on a case-by-base basis.12 This 
remains. Because the IAAF believes testosterone to be the most significant trait 
enhancing athletic performance, the IAAF feels hyperandrogenic women have an 
unfair performance advantage over other female athletes. To the IAAF, this belief 
results in requiring these hyperandrogenic female athletes to actively lower their 
testosterone levels. The IAAF has taken this stance to ensure fair, level competition, 
understanding that in these circumstances, nobody is cheating and this is purely a 
biological issue.13  
III. Overview of laws in place 
Who is the IAAF 
The IAAF is the governing body of world competition, making the rules 
and decisions regarding equipment and doping in international track and field 
competition.14 The organization is a signatory of the World Anti-Doping Code, 
rules that have been adopted by the IAAF Council.15 The Athletics Integrity Unit 
enforces these rules on international-level athletes and athletic personnel in regards 
to “education, testing, investigations, results management, hearings, sanctions, and 
appeals.”16 In implementing these rules, the Athletics Integrity Unit board appoints 
an Independent Anti-Doping Review Panel approves, monitors, and provides 
suggestions regarding the anti-doping program, advising the Athletics Integrity 
Unit on anti-doping.17 The IAAF and the International Olympic Committee (IOC) 
have spent over half a century aggressively trying to determine who is a woman for 
the purposes of international competition.  
                                               
9 M.L. Healy et al., Endocrine profiles in 693 elite athletes in the post competition setting, 81 Clinical 
Endocrinology, 294, 298 (2014).  
10 Hyperandrogenism explained and what it means for athletics, USA Today, Aug. 2, 2016. 
11 Id.  
12 Hyperandrogenism explained and what it means for athletics, USA Today, Aug. 2, 2016. 
13 Id. 
14 International Association of Athletics Federations, About the IAAF, https://www.iaaf.org/about-iaaf. 
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What is “doping” 
 The definition of doping is multidimensional. It is the “presence of a 
prohibited substance or its metabolites or markers in an athlete’s sample.”18 It is the 
“use or attempted use by an athlete of a prohibited substance or a prohibited 
method.”19 Doping is also “evading, refusing or failing to submit to sample 
collection”, “tampering or attempted tampering with any part of doping control”, 
“possession of a prohibited substance or a prohibited method”, “trafficking or 
attempted trafficking in any prohibited substance or prohibited method”, 
complicity, prohibited association, and the administration or attempted 
administration of a prohibited substance or method to any athlete in or out of 
competition.20 Lastly, doping is “any combination of three missed tests and/or filing 
failures.” 21  In other words, an athlete is “doping” if she is born with what is 
considered a “banned substance” such as a certain level of testosterone. 
Banned Substances 
 The World Anti-Doping Agency (WADA) establishes the list of prohibited 
substances. A list is established every year and is valid from January 1 to December 
31 of that year. Some substances are prohibited both in and out of competition while 
other substances are only banned in competition. There are also banned substances 
specific to sport. These banned “substances” include both substances and methods.  
 The following substances are banned in and out of competition: anabolic 
agents; peptide hormones, growth factors, and related substances and mimetics; 
beta-2 agonists; hormone and metabolic modulators; diuretics and masking agents; 
and non-approved substances.22 The following are methods banned in and out of 
competition: manipulation of blood and blood components; chemical and physical 
manipulation; and gene doping.23 
An example of an anabolic agent is an anabolic androgenic steroid. 
Testosterone is an endogenous anabolic androgenic steroid. Testosterone is a 
banned substance because of its numerous “potential” performance-enhancing 
effects. These include “boosting the oxygen-carrying capacity of the blood, 
building lean muscle mass and increasing mental drive and aggressiveness.”24 
                                               
18 Anti-Doping Rule Violation 2.1.1. 
19 Anti-Doping Rule Violation 2.2. 
20 Anti-Doping Rule Violation 2.3, 2.5-2.10. 
21 Anti-Doping Rule Violation 2.4. 
22 World Anti-Doping Agency, What is prohibited, 2017, https://www.wada-ama.org/en/prohibited-list/ 
prohibited-at-all-times. 
23 Id. 
24 Martha Kelner and James Rudd, Caster Semenya could be forced to undertake hormone therapy for future 
Olympics, The Guardian, July 3, 2017.  




Some studies indicate female athletes might experience “improved visuospatial 
abilities.”25  
Permitted Substances & Treatments, Exceptions 
With respect to testosterone, a female athlete is eligible to compete in the 
women’s competitions if she has blood testosterone levels below 10 nmol/L, which 
is the lower limit of testosterone for men.26 Anything above 10 nmol/L is 
considered an advantage that is subject to the anti-doping regulations, even if that 
testosterone level is naturally occurring. 
Testing 
Under the Anti-Doping Rules, testing and investigating shall only occur for 
anti-doping purposes.27 Testing athletes provides evidence of compliance or non-
compliance with the Anti-Doping regulations. When there are findings adverse to 
the Anti-Doping regulations, investigations will occur to gather intelligence and 
evidence to determine whether a violation actually occurred. Investigations are not 
limited to adverse findings. Any athlete, who has not retired, may be subject to 
testing. The Integrity Unit plus any anti-doping organization with testing 
authoritative powers, can require an athlete to provide a sample at anytime and  
anyplace.28 This includes athletes serving a suspension or period of ineligibility.29 
Testing for and diagnosis of hyperandrogenism in the elite international 
athletic world “considers only high testosterone and tissue sensitivity.”30 The IAAF 
and IOC use serum testosterone as the sole biological variable to regulate women’s 
participants’ eligibility.31 Female athletes with testosterone levels about 10 nmol/L 
are required to either (1) undergo medical intervention to lower the levels or (2) 
risk being banned from women’s events.32 These testosterone levels and 
hyperandrogenism under the IAAF are determined through “systematic hormonal 
screening” to fulfill the “athlete biological passport [ABP].”33 The ABP monitors 
“selected biological variables over time that indirectly reveal the effects of doping 
rather than attempting to detect the doping substance or method itself.”34  
                                               
25 Id. 
26 Peter Sonsken et al., Medical and Ethical Concerns Regarding Women with Hyperandrogenism and Elite Sport, 
The Journal of Clinical Endocrinology and Metabolism, 825 (Mar. 1, 2015).  
27 IAAF Anti-Doping Rules 5.1. 
28 IAAF Anti-Doping Rules 5.2.1. 
29 Id. 
30 Rebecca M. Jordan Young, Peter H. Sonsken, and Katrina Karkazis, Sex, health, and athletes, BMJ, at 1, Apr. 28, 
2014. 
31 Peter Sonsken et al., Medical and Ethical Concerns Regarding Women with Hyperandrogenism and Elite Sport, 
The Journal of Clinical Endocrinology and Metabolism, 825, 825 (Mar. 1, 2015).  
32 Id. 
33 Rebecca M. Jordan Young at 2. 
34 World Anti-Doping Agency, Athlete Biological Passport, 2017, https://www.wada-ama.org/en/athlete- 
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Under the IAAF, full testing processes for testosterone begin with a clinical 
examination and endocrine assessment that determines whether or not there are 
grounds for classifying a female athlete as hyperandrogenic.35 If such grounds are 
found, at least a full physical and gynecological examination incur, with endocrine 
assessments of blood and urine, medical history including family medical history, 
and psychological assessments. 36 This includes “measuring and palpating the 
clitoris, vagina and vulva, as well as evaluating breast size and pubic hair scored on 
an illustrated five-grade scale.”37 
Organizations like the IAAF “integrate the Athlete Biological Passport into 
the larger framework of robust anti-doping program in order to: [i]dentify and target 
athletes for specific analytical testing by intelligent and timely interpretation of 
Passport data; and [p]ursue possible anti-doping rule violations based on atypical 
passport [. . .] .“38 In other words, while the ABP requires the IAAF to regulate 
doping, the IAAF chooses to implement the highly questionable, unideal 
regulations on natural testosterone.  
Proof of doping 
The IAAF, or other Anti-Doping organization with power, has the burden 
of establishing that an anti-doping violation has occurred.39 The IAAF or other 
organization, has to establish “the commission of the alleged Anti-Doping Rule 
Violation to the comfortable satisfaction of the hearing panel, bearing in mind the 
seriousness of the allegation that is made.”40 This standard of proof is not to the 
level of beyond a reasonable doubt and is somewhere between preponderance of 
the evidence and clear and convincing evidence. Facts proving an anti-doping 
violation “may be established by any means”, which includes the following: 
admissions; analytical methods; compliance with an official international standard; 
WADA-accredited and WADA-approved laboratories; those facts established by 
“a court or professional disciplinary tribunal of competent jurisdiction that is not 
the subject of a pending appeal”; and inferences drawn by a hearing panel in a 
hearing based on the accused’s refusal or failure to respond to questions from an 
investigation or requests prior to a hearing.41 
                                               
biological-passport. 
35 Jordan Young at 2. 
36 Rebecca M. Jordan Young, Peter H. Sonsken, and Katrina Karkazis, Sex, health, and athletes, BMJ, at 2, Apr. 28, 
2014. 
37 Ruth Padawer, The Humiliating Practice of Sex-Testing Female Athletes, The New York Times, Jun. 28, 2016. 
38 World Anti-Doping Agency, Athlete Biological Passport, 2017, https://www.wada-ama.org/en/athlete- 
biological-passport. 
39 IAAF Anti-Doping Rules 3.1. 
40 Id. 
41 IAAF Anti-Doping Rules 3.2. 




On rebuttal, the athlete, or whoever is alleged to have committed the 
violation, has to refute the established presumption or establish specific facts or 
circumstances by a preponderance of the evidence, or “a balance of probability.”42  
Managing Results & Hearing 
 Results management & investigation 
 Hearings and managing athlete testing results are governed by the 
procedural rules of the national federation or Anti-Doping organization that 
initiated or directed the athlete testing and sample collection.43 However, the 
Integrity Unit, under the Anti-Doping Rules, has responsibility over results 
management for investigations conducted by the Integrity Unit; possible violations 
that arise where there has been testing conducted under the Anti-Doping Rules; 
violations that arise where no testing has occurred; a National Anti-Doping 
organization initiated the sample collection; and for a filing failure or missed test. 
The Integrity Unit also oversees adverse ABP findings. 
After the results management or investigation process by the Integrity Unit, 
National Federation, or National Anti-Doping organization, if an Anti-Doping 
Rules violation is asserted, the athlete or the person who committed the violation 
will be notified of a violation and referred to a hearing.44 
Hearing  
The Disciplinary Tribunal is the IAAF established “court” with jurisdiction 
over Anti-Doping Rules violations asserted by the Integrity Unit, National 
Federation, or other National Anti-Doping organization.45  The Disciplinary 
Tribunal has the following powers:  
“to rule on its own jurisdiction; to appoint an independent expert to assist or advise 
it on specific issues [. . .]; to expedite or to adjourn, postpone or suspend its 
proceedings, upon such terms as it will determine, where fairness so requires; to 
extend or abbreviate any time limit specified in any rules or by the Disciplinary 
Tribunal itself; to order any party to make any property, document or other thing in 
its possession or under its control available for inspection; to allow one or more 
third parties to intervene or be joined in the proceedings, to make all appropriate 
procedural directions in relation to such intervention or joinder, and thereafter to 
make a single final decision or separate decisions in respect of all parties; to order 
that certain preliminary and/or potentially dispositive questions [. . .] be heard and 
determined in advance of any other issues in the matter; to award interim relief or 
other conservatory measures on a provisional basis and subject to final 
determination; to make any other procedural direction or take any other procedural 
                                               
42 Id. 
43 IAAF Anti-Doping Rules 7.1. 
44 IAAF Anti-Doping Rule 8.1. 
45 Id. 
2019                Santa Clara Journal of International Law 7:2 
8 
 
steps which the Disciplinary Tribunal considers to be appropriate in pursuit of the 
efficient and proportionate management of any proceeding or matter pending 
before it; and to impose costs orders.”46 
Hearings before the Disciplinary Tribunal begin with the head of the 
Integrity Unit sending the “Notice of Charge” (written notice) to both the athlete or 
person charged with the violation and the Disciplinary Tribunal chairperson.47 This 
notice outlines the violations that have taken place, the Anti-Doping rule that has 
been breached, a summary of the facts that are the basis for the allegation, the 
applicable consequences, matters related to provision suspension, and the fact that 
the athlete is entitled to respond to the notice.48 
The person charged with the violation may respond in a number of ways: 
admit to the charge and acquiesce to the consequences; admit to the charge but 
dispute or attempt to mitigate the consequences; or deny the violation and have the 
Disciplinary Tribunal decide, at the hearing, the charge, if it is upheld, and any 
consequences.49  
Upon receiving the notice of charge, the chairperson appoints one or three 
members of the entire Disciplinary Tribunal to hear the case and decide the 
violations alleged in the notice. Appointees cannot be involved if they have any 
personal connection or interest to anyone involved; had any prior involvement with 
any matter or facts giving rise to the proceedings; is the same nationality as the 
party charged; or if impartiality or independence would be questioned as 
determined by the chairperson.50  
Both the Integrity Unit and the charged person have the right to be present 
and heard at the hearing as well as be represented by legal counsel.51 The charged 
person may also submit a writing for the Disciplinary Tribunal panel to consider in 
its deliberations.52 The hearings are conducted confidentially.53 After all 
submissions, the Disciplinary Tribunal panel deliberates whether a violation has 
occurred and what the consequence should be. The panel issues their decision, in 
writing, within 14 days of the conclusion of the hearing, and sends the decision to 
the parties, WADA, and whoever else has a right to appeal the decision. This 
written decision contains and explains the findings, whether a violation has 
occurred, the consequences, why the maximum consequence has not occurred, the 
                                               
46 IAAF Anti-Doping Rule 8.6.1. 
47 IAAF Anti-Doping Rule 8.6.1. 
48 IAAF Anti-Doping Rule 8.4.2. 
49 IAAF Anti-Doping Rule 8.4.3. 
50 IAAF Anti-Doping Rule 8.5.2. 
51 IAAF Anti-Doping Rule 8.8.2. 
52 IAAF Anti-Doping Rule 8.8.3. 
53 IAAF Anti-Doping Rule 8.8.1. 




date the consequence begins, the reasons of all the aforementioned, and the rights 
surrounding appeal.54 
Consequences 
Anti-Doping violations have a number of consequences. Where there is an 
Anti-Doping violation found from an in-competition test, the athlete is 
automatically disqualified and forfeits medals, titles, awards, points, and prize and 
appearance money.55 Results from other events the athlete has competed in may 
also be disqualified.56 Consequences can vary greatly depending on whether it is 
the athlete’s first offense and the degree of fault the offender has in the offense.  
Where an athlete has committed an Anti-Doping violation, and it is the 
athlete’s first Anti-Doping offense, the athlete shall be ineligible for four years 
where the violation either did not involve a specified substance or does involve a 
specified substance but the violation was unintentional.57  The period of ineligibility 
is two years where the athlete, who failed to submit a sample, can show that the 
violation was unintentional. For a first offense, the two year period of ineligibility 
can be reduced to one year if the degree of fault is lower.58 Where the athlete or 
person who committed the violation can prove that he or she was simply negligent 
or bears no fault at all, than the period of ineligibility is eliminated.59  
The period of ineligibility may be eliminated, reduced, or suspended for 
reasons that are not fault-related. One reason is substantially assisting the Integrity 
Unit in discovering or establishing Anti-Doping Rule violations.60 Another reason 
is where an athlete or other violator voluntarily admits to committing a violation 
before other evidence has been established.61 
Where the violation is the athlete or offender’s second offense, the period 
of ineligibility is one of the following, whatever is greater: “six months; one-half 
of the period of ineligibility imposed for the first anti-doping offense without taking 
into account any reduction [. . .]; or twice the period of ineligibility that would be 
applicable to the second Anti-Doping Rule violation if it were a first Anti-Doping 
Rule violation, without taking into account any reduction [. . .].”62 Where a prior 
violation has occurred within ten years of the recent violation, that prior violation 
shall be taken into account to calculate the period of ineligibility.63 When multiple 
                                               
54 IAAF Anti-Doping Rule 8.9.2. 
55 IAAF Anti-Doping Rule 9.1. 
56 IAAF Anti-Doping Rule 10.1. 
57 IAAF Anti-Doping Rule 10.2.1. 
58 IAAF Anti-Doping Rule 10.3.2. 
59 IAAF Anti-Doping Rule 10.4. 
60 IAAF Anti-Doping Rule 10.6.1. 
61 IAAF Anti-Doping Rule 10.6.2. 
62 IAAF Anti-Doping Rule 10.7.1. 
63 IAAF Anti-Doping Rule 10.7.5. 
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violations have taken place at once, the ineligibility periods for each offense shall 
run sequentially.64  
Appealing 
 Athletes and others found to have committed an Anti-Doping Rules 
violation may appeal the decision. For international-level athletes or athlete support 
persons, or those involving international competitions, a decision can be appealed 
exclusively to the Court of Arbitration for Sport (CAS).65 Disciplinary Tribunal 
decisions may also be appealed exclusively to CAS.66 All other decisions “may be 
appealed to an independent and impartial body in accordance with rules established 
by the National Federation or National Anti-Doping Organisation.”67 WADA can 
appeal a decision that was not rendered in a timely manner.68 
 Appealing to CAS must occur within 30 days from receipt of the decision. 
Appeals must be filed with the CAS and IAAF on the same day69. Respondent has 
30 days to file an answer with the CAS after receiving the appeal brief.70 Taking on 
an appeal is up for the Anti-Doping Review Panel to decide. The CAS Code of 
Sports-related Arbitration applies. Cross appeals and subsequent appeals are 
permitted. Where the IAAF is involved, the CAS panel is bound by IAAF 
constitution, rules, and regulations.71 The CAS’ decision is final and binding on all 
parties and there is no right of appeal from the decision. 72 
Luckily, the court of arbitration for sport has temporarily suspended the 
IAAF’s disciplinary practices in regard to restricting permitted levels of 
testosterone among female competitors. Nonetheless, the IAAF continues to this 
day to stand by and argue for these practices, giving this paper relevance. 
IV. Argument & Analysis 
The IAAF discriminates against female athletes with atypical sex 
development. One highly publicized example of this, that will be discussed further 
below, is the case of Dutee Chand. The IAAF uses advanced technology to 
inequitably punish female athletes born intersex. These uses are intrusive, violative, 
and often quite embarrassing to the female athletes, resulting in arbitrary 
conclusions and decisions. Rather, the IAAF should and can use modern-day 
technology to create and implement rules regarding testosterone doping in a more 
just way.  They have all the right tools, boards, and actors in place to make the right 
                                               
64 IAAF Anti-Doping Rule 10.7.6. 
65 IAAF Anti-Doping Rule 13.2.2. 
66 IAAF Anti-Doping Rule 13.2.3. 
67 IAAF Anti-Doping Rule 13.2.3. 
68 IAAF Anti-Doping Rule 13.3. 
69 IAAF Anti-Doping Rule 13.7.1. 
70 Id. 
71 IAAF Anti-Doping Rule 13.9.4. 
72 IAAF Anti-Doping Rule 13.9.6. 




decisions, they just fail to fully utilize all the resources available to their fullest 
capacity.  
The IAAF and IOC concern for testosterone doping are understandable. 
Fairness is allegedly one of the most important principles to the IAAF and IOC, 
and testosterone is the “most widely abused performance-enhancing drug.”73 64 of 
116 female athletes serving doping bans as of December 2016 tested positive for 
androgens, or testosterone.74 The advantages from heightened testosterone levels 
are, to the IAAF and their medical and science personnel, potentially quite 
significant. At times the IAAF has been successful and just in monitoring doping 
in female athletes. 
For instance, the IAAF successfully found and penalized Russian sprinters 
who had engaged in doping. Russia had state-sanctioned androgenic doping, and 
Russian 800-meter 2012 London Olympic gold medalist Mariya Savinova was 
stripped of her medal.75 She received a four-year ban and nullification of her July 
2010 to August 2013 race results by the CAS for doping during that time period. 
Savinova’s biological passport plus her videotaped admission of taking 
oxandrolone, an anabolic steroid, were the CAS’ clear evidence of Savinova’s 
doping.76 In the video, Savinova described how her coach, her husband, and others 
had tested for and designed a sophisticated system for the oxandrolone to be in and 
out of her body in 20 days.77 At least nineteen other Russian athletes have been 
stripped of their 2008 or 2012 Olympics medals.78 As a result of this widespread, 
systemic doping, the entire Russian track and field team was barred from competing 
in the 2016 Olympic games in Rio.79 Consequently, Russia was also barred from 
competing in the 2017 World Championships in London.80 This crackdown on 
Russian female track doping is unrelated to naturally occurring high levels of 
testosterone, and the action taken against Russia - the bans - is an understandable 
punishment that furthers the interests of fairness. 
While the IAAF may have the proper processes in place to make the best 
decisions regarding doping with people actively taking banned substances and 
methods, there are still many ways in which the IAAF is in the wrong. The IAAF’s 
regulations of testosterone levels and hyperandrogenism in female athletes are 
                                               
73 Martha Kelner and James Rudd, Caster Semenya could be forced to undertake hormone therapy for future 
Olympics, The Guardian, July 3, 2017. 
74 Martha Kelner and James Rudd, Caster Semenya could be forced to undertake hormone therapy for future 
Olympics, The Guardian, July 3, 2017.  
75 Colleen Curry, The face of Russia’s doping scandal: Mariya Savinova, The Guardian, Nov. 10, 2015. 
76 Marissa Payne, Russian runner who admitted on video to doping is stripped of Olympic gold, The Washington 
Post, Feb. 10, 2017.  
77 Id. 
78 Marissa Payne, Russian runner who admitted on video to doping is stripped of Olympic gold, The Washington 
Post, Feb. 10, 2017.  
79 Id. 
80 Id. 
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discriminatory, in opposition to the Olympic charter, unethical, and wholly without 
scientific backing. 
Discriminatory 
 The IAAF regulations on testosterone and who is woman enough to 
participate are discriminatory against women and consequently discriminatory 
against particular athletes because of their success. Men are not regulated nearly as 
vigorously as women. These regulations on hyperandrogenism in women came to 
fruition as a response to the success of Caster Semenya and are executed upon 
suspicion that follows successful women track athletes such as Dutee Chand. 
Following a discussion of the differences in IAAF treatment of men, the stories of 
Semenya and Chand will be discussed further below.  
Male athletes do not undergo even remotely similar invasive, dehumanizing 
testing procedures as female athletes. There are no regulations of naturally 
occurring advantages in male athletes. There never have been.  In fact, these 
naturally occurring higher levels of testosterone in male athletes are praised. 
Furthermore, the regulation of the “presence of a prohibited substance or its 
metabolites or markers in an athlete’s sample” such as naturally occurring high 
levels of testosterone is discriminatorily practiced. Male athletes are not kept under 
as watchful an eye as female athletes in regards to testosterone levels. Additionally, 
female athletes are penalized for success, with the IAAF harshly coming down on 
female athletes whose success is questioned as being the result of high testosterone. 
The same cannot be said for the treatment and penalization of male athletes for 
testosterone. 
Caster Semenya 
 Caster Semenya is a South African middle distance runner and 2016 
Olympic gold medalist. After the 2009 Berlin world championships, in which 
Semenya, took 1st in the 800m, the IAAF received criticism for not properly 
investigating her.81 The public questioned Semenya’s success as being a result of 
high levels of testosterone, and in response the IAAF subjected Semenya to 
“unwarranted and invasive scrutiny of the most intimate and private details” of 
Semenya’s being. Semenya won the 2009 World Championships by a full two 
seconds. Afterward, people insultingly called her a man. She was punished for 
“being too fast and supposedly too masculine.”82 This was the catalyst for the 
current policies the IAAF enacted in 2011.   
If the IAAF has their way, Semenya, and other female athletes in the future, 
could be forced to undertake hormone therapy for future Olympics and international 
                                               
81 International Association of Athletics Federations, Semenya Rockets to the Top of the World, Aug. 26, 2009, 
https://www.iaaf.org/competitions/iaaf-world-championships/news/semenyas-Rockets- 
to-the-top-of-the-world. 
82 Jere Longman, Understanding the Controversy Over Caster Semenya, The New York Times, Aug. 18, 2016. 




competition.83 Male athletes do not face such threats of force. Male athletes are not 
faced with invasive procedures and being thoroughly embarrassed the way 
Semenya and other female athletes are made to feel. This treatment of Semenya 
stemmed from negative, weak people upset with her success, something else that 
does not happen to male athletes.  
Dutee Chand 
Dutee Chand is a record-breaking Indian sprinter. Her story and battle 
against the IAAF, documented by The New York Times, started in June 2014, when 
Chand was called in by the director of the Athletics Federation of India - the Indian 
affiliate of the IAAF - to meet in Delhi.84 Upon arriving in Delhi, Chand was sent 
to a clinic to meet with a doctor for the Athletics Federation of India, and instead 
of being given a standard urine or blood test, the doctor said he would perform an 
ultrasound. She was confused, but the doctor assured her it was routine. 
In fact, the ultrasound test was prompted by Chand’s stellar performance at 
the Asian Junior Athletics Championships (AJAC). In response to her surprising 
successful performance, people began to question her testosterone status. Chand’s 
muscles were quite pronounced in comparison to other women, and she had a stride 
people believed too impressive for someone of her stature. A few days after the 
ultrasound, Chand received a letter in the mail requesting she do a gender 
verification test. Within days Chand was sent to a private hospital and had her blood 
drawn for her natural level of testosterone to be measured. Chand also received 
chromosome analysis, an MRI and another gynecological exam. The results of her 
tests indicated that her “male hormone” levels were above the “typical female 
range,” which meant within the male range. Chand was banned from racing because 
the IAAF feared she would have a competitive advantage from the excess 
testosterone. 
Chand appealed her ban to the CAS, arguing the IAAF’s regulations 
discriminated against female athletes with “a particular natural physical 
characteristic.”85 Though the IAAF disputed Chand’s arguments, the CAS found in 
favor of Chand, finding in particular that other factors contribute to elite athletic 
performance, not solely testosterone. This will be further explored in a later section. 
The CAS’ findings required the IOC establish policy or guidelines for intersex at 
the 2016 Rio Olympics, and the IOC instead urged the IAAF to show the CAS 
evidence in support of the reinstatement of the IAAF rules on hyperandrogenism. 
Chand participated in the Rio Olympics, where she did not even qualify for the 100-
meter semifinals. 
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Chand’s failure to advance to the 100-meter semifinals at the Rio Olympics 
is prime evidence the IAAF’s understanding of the beneficial effects of naturally 
occurring high levels of testosterone is misguided and useless. The differences in 
Semenya’s performance - gold - and Chand’s performance - did not advance to the 
semifinals - alone showcase how unreliable testosterone levels can indicate 
performance advantages. The IAAF’s failed actions resulted in them extending an 
invitation to Chand to the world championships, a seeming concession to their 
failed policy and actions. In spite of evidence of the IAAF’s failed, useless 
regulations, the IAAF still argues for and pushes these regulations and their 
usefulness. The IAAF is still seeking a court ruling in favor of its policies and 
procedures.86 
The regulations will, and do, unnecessarily and negatively affect women 
with intersex conditions that result in high testosterone levels instead of solely 
punishing the female athletes who are actually doping with testosterone. These 
IAAF regulations on testosterone and hyperandrogenism further discriminate 
against women by causing women to live in fear, to live with concerns that their 
male counterparts do not experience. Women have added stressors and pressures 
other than making sure they prepare their bodies for elite competition; they must 
worry about something entirely out of their control, something their body naturally 
produces. Semenya and Chand’s experiences are prime examples of the 
discrimination women track athletes experience that men do not. The male track 
athletes do not have to take drugs to suppress their natural hormones, they do not 
have to have surgery that is not medically required, and they do not undergo the 
social backlash and exposure of their private lives. The IAAF discriminates against 
women, particularly intersex and hyperandrogenic women, and this discrimination 
is in direct opposition to the Olympic charter. 
In opposition to the Olympic charter 
The Olympic charter codifies the “fundamental principles of Olympism.”87 
The charter also establishes the relationship between the international federations 
associated with the Olympics and the Olympics themselves. IAAF regulations are 
in opposition to Principle 6 of the Olympic charter. Principle 6 states “any form of 
discrimination affecting the Olympic Movement” is prohibited.88  
At the minimum, there should be a fairness applicable to all women, if not 
all men, too. A woman who has been living as a woman her whole life, and who 
has not doped, should be able to compete as a woman. Additionally, women should 
not have to forfeit the opportunity to represent their country because of the way 
their body naturally functions, especially if the options are do not compete at all or 
undergo invasive, embarrassing hormone therapy and surgery. 
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Lack scientific backing 
The medical decisions in Olympic female athlete hyperandrogenism cases 
have absolutely no scientific backing. 
IAAF health and science department researchers conducted a study and 
concluded that the heightened testosterone levels in elite female track athletes 
provided an impactful performance boost. 1,332 female athletes, competing in 
various track and field events at the 2011 and 2013 world championships, had their 
blood testosterone levels measured.89 The results of the study indicated that those 
participants with the highest levels of testosterone demonstrated “significant 
advantages” or, in other words, ran faster than those participants with the lowest 
levels of testosterone. The head researcher found this to be “new evidence [of] the 
performance-enhancing effects of androgens in elite female athletes.”90 However, 
this understanding of how testosterone works in athletes has been rebutted by other 
reputable scientists and studies.  
The assumption that the naturally occurring high levels of testosterone give 
an unfair advantage in competition is woefully misguided, as evidenced by Dutee 
Chand failing to make it past the first round at the 2017 World Athletic 
Championships. Success can be attributed to many other factors such as genes on 
the Y chromosome that control height and lean body mass.91 Body composition is 
a key feature in elite sports.92 In 2014, a study measuring the profile of hormones 
in a select group of elite athletes was published in Clinical Endocrinology.93 Blood 
samples from 813 volunteer elite athletes from 15 different sport categories were 
obtained. A subset of 693 of the 813 had their endocrine profile measured. These 
samples were drawn within two hours post major national or international 
competition. The study obtained hormone profiles on 454 male and 239 female 
athletes. This was the first study to document hormone profiles in elite male and 
female athletes. The study’s findings are significant to debunk IAAF and IOC 
beliefs about the “normal” testosterone levels in a woman.  
The first finding to puncture a hole in the IAAF’s ill-informed belief in 
testosterone levels indicating who is “woman” enough to perform is the impact of 
lean body mass (LBM) on performance. Difference in LBM sufficiently accounts 
for observed differences in strength and performance. The study found that women 
had an LBM of 85% that of men, a 10-kg difference in LBM in elite female athletes, 
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and that LBM is the most likely explanation for differences in performance, not 
testosterone.94 
The elite female athletes had high levels of testosterone, the upper limit of 
the normal male range, but the normal serum testosterone (LH) and follicle-
stimulating hormone (FSH) in those women indicates women may have had other 
issues such as androgen insensitivity syndrome, polycystic ovary syndrome, or 
hyperandrogenism.95 The high levels do not indicate a competitive advantage or 
intentional doping. 
Additionally, the study found low serum testosterone values in the elite 
male athletes, another indicator that serum testosterone does not determine athletic 
performance.96 These male athletes run faster than the female athletes, running 
some of the fastest times in history, but they have low testosterone levels at 
performance time, indicating how little role testosterone can have in performance. 
Athletes had different mean testosterone levels between genders, but there existed 
a complete overlap of the range of testosterone concentrations. This overlap 
indicates that limiting participation of female athletes based on “normal” serum 
testosterone levels is incorrect and in need of overhaul. 
The study concluded there is “no clear separation between the testosterone 
levels of male and female elite athletes.”97 The findings of this study totally negate 
the IAAF and IOC belief that testosterone levels determine performance and 
competitive advantage and restriction of women without “normal” serum 
testosterone levels. Elite female athletes as a group generally have higher 
testosterone levels than the average woman.98 Raised levels of testosterone in 
women can be caused by other occurrences and wholly unrelated to unfair doping, 
such as cysts or other ovarian syndromes.99 
Anti-doping regulations are in place to punish people who are cheating, and 
satisfy that purpose in instances like the Russian doping scandal. However, the 
IAAF director has already admitted hyperandrogenism is not an issue of cheating 
because no one is cheating.100 He acknowledged this is a biological issue. Perhaps 
he should seriously consider what the biological experts know. 
Violating ethical standards  
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The medical practices required by the IAAF standards violate the ethical 
standards of clinical practice. 
A study in France that was carried out in a way that mirrored IAAF testing 
was found to violate ethical standards of clinical practice.101 The Sonsken piece 
found that since those practices were the same as the IAAF testing practices and 
found unethical, than the IAAF practices are surely unethical.102 The study found 
devastating effects on athletes due to the trauma from the testing and having their 
identity questioned.103  
Other unethical practices the study explored the IAAF has also carried out. 
For example, the IAAF gender requirements and testing result in unnecessary 
surgeries and medical procedures, just as the France study did.104 Other non-athlete 
women with similar biological characteristics do not require these same surgeries 
or procedures. This raises serious ethical concerns since the testing and practices 
are only needed for eligibility purposes, not health purposes. Practices in the study 
and suggested by the IAAF, like the removal of gonads and clitoral mutilation for 
the purposes of athletic eligibility, are unethical especially since hyperandrogenism 
does not cause morbidity or indicate disease, which actually warrant the removal 
of gonads and clitoral mutilation. 105 In fact, the IAAF regulations to lower 
testosterone levels directly conflict with the medical approach to 
hyperandrogenism.106 The IAAF offers to pay for some procedures, not all, and 
does not provide for after care.107 This is sure to have a negative impact on athletes 
from regions lacking the resources for necessary medical supervision and long-term 
follow up.108 For the athletes who require lifelong hormone replacement, the 
upkeep might be entirely too expensive.  The short term and long term medical 
implications of these unnecessary procedures are widespread. Such practices are 
unacceptable in the medical field outside the IAAF realm. 
These policies, practices and effects trickle down and extend beyond elite, 
international level competitors. The IOC requires national Olympic committees 
“‘actively investigate any perceived deviation in sex characteristics’ before 
registering athletes.”109 India has already created a policy for discerning sex 
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characteristics that applies to women athletes at every level.110 Four young female 
athletes, ages 18 to 21, have already undergone unnecessary gonadectomy 
procedures to comply with IOC requirements.111 They were subject to more than 
the average procedures, undergoing “karyotyping and genetic analysis, abdominal-
pelvic magnetic resonance imaging, and radiography to determine bone mineral 
density and composition.”112 In a traditional medical scenario, doctors, at least in 
the United States, would likely have their licenses revoked for such practices.
 The IAAFs procedures are invasive, irreversible, and potentially 
widespread.113 Due to the IOC mandate to investigate any perceived abnormal sex 
characteristics in athletes, young female athletes are subject to gonadectomy 
procedures and partial clitoridectomies to achieve the requisite womanhood.114 
Because of the testosterone limits allowed in women athletes, 14% of women 
athletes are subject to being investigated for “hyperandrogenism”, and all the 
invasive, unethical procedures that come with it.115 
V. Conclusion 
Going forward, it appears the IAAF and IOC have only two options: adapt 
or cease to exist. People, sports fans and participants domestically and 
internationally, will find a way to overhaul the IAAF and their unethical, 
discriminatory practices. To avoid dying out, the IAAF first needs to make and 
apply rules equally to men and women, and these rules need to completely disregard 
the way someone was born. If the IAAF wants to keep these stringent rules, 
punishing female athletes with naturally occurring high levels of testosterone then 
the IAAF must do the same for male athletes. In the greatest interest of fairness, the 
regulations regarding the eligibility of hyperandrogenic women athletes, including 
the unnecessarily invasive medical intervention and “corrective” treatments, should 
be rescinded immediately. At the end of the day, if a woman has lived as a woman 
her whole life, the IAAF should, and frankly must, let her compete with the women. 
The counter to this argument is the question of how do transgender athletes fit in, 
but that is outside the scope of this paper. 
In every other field, the law changes as the times change, as more people 
come to recognize what is right and what is clearly so very wrong. Slavery. 
Women’s suffrage. Jim Crow. Gay rights. Just as those have changed, so the IAAF 
needs to change. And the IAAF needs to learn from history. Most of those historical 
changes occurred much later than they could and should have. People surely 
regretted being on the wrong side of history. The IAAF must do all it can to avoid 
having those regrets, too. 
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